Cabozantinib for different endocrine tumours: killing two birds with one stone. A systematic review of the literature
Authors:
Open Access
- 18 October 2023
- journal article
- review article
- Published by Springer Nature in Endocrine
- Vol. 83 (1) , 26-40
Abstract
Purpose Cabozantinib is an oral multi-tyrosine kinase inhibitor (TKI) that has been approved in Europe for advanced renal cell carcinoma, hepatocellular carcinoma, locally advanced and metastatic medullary thyroid carcinoma (MTC) and radioiodine-refractory differentiated thyroid cancer. Merkel cell carcinoma (MCC) is a rare and highly aggressive cutaneous malignant neuroendocrine tumour that usually presents in sun-exposed skin areas of immunosuppressed patients. Conflicting data exist about cabozantinib for MCC and this TKI is currently under investigation in several onco-endocrine frameworks. Methods We herein report a case of an 83-year-old man who was diagnosed with MCC during the treatment of an advanced metastatic MTC. The diagnosis of MCC was established based on clinical, histopathologic evaluation and immunohistochemistry. A systematic review of the literature on cabozantinib use for advanced endocrine and neuroendocrine tumours has been performed. Results The patient was initially treated with surgery and adjuvant radiotherapy. Cabozantinib was therefore started to control both MTC and MCC. After 24 months, no sign of local or metastatic MCC relapse was evidenced. Conclusion Promising data on cabozantinib treatment for endocrine and neuroendocrine neoplasms is recently emerging in the literature. In our clinical case, we reported that, besides the good response for the MTC, cabozantinib also seems to effectively control metastatic MCC, along with efficient surgery and adjuvant radiotherapy. Further investigations are needed to determine the efficacy and safety of cabozantinib in MCC patients and in off-label endocrine tumours.Keywords
This publication has 81 references indexed in Scilit:
- The management of head-and-neck paragangliomasEndocrine-Related Cancer, 2013
- Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinomaEuropean Journal of Endocrinology, 2012
- Suppression of Tumor Invasion and Metastasis by Concurrent Inhibition of c-Met and VEGF Signaling in Pancreatic Neuroendocrine TumorsCancer Discovery, 2012
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor GrowthMolecular Cancer Therapeutics, 2011
- Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid CancerJournal of Clinical Oncology, 2011
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United StatesJournal of Clinical Oncology, 2008
- RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancerExpert Review of Anticancer Therapy, 2008
- Utilization of the PICO framework to improve searching PubMed for clinical questionsBMC Medical Informatics and Decision Making, 2007
- Adjuvant Mitotane Treatment for Adrenocortical CarcinomaNew England Journal of Medicine, 2007